A Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Topic Trial)
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Ivacaftor (Primary)
- Indications Chronic bronchitis; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Acronyms The Topic Trial
- 18 Jul 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 18 Jul 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 31 Aug 2018 Biomarkers information updated